Request Demo
Last update 27 Feb 2026
Xentuzumab
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms BI-836845 |
Target |
Action inhibitors |
Mechanism IGF-1 inhibitors(Insulin-like growth factor I inhibitors), IGF-2 inhibitors(Insulin-like growth factor II inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 164717H
Source: *****
Sequence Code 164724L
Source: *****
Related
9
Clinical Trials associated with XentuzumabNCT05110495
Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN)
NCT03659136
XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
NCT03099174
An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.
100 Clinical Results associated with Xentuzumab
Login to view more data
100 Translational Medicine associated with Xentuzumab
Login to view more data
100 Patents (Medical) associated with Xentuzumab
Login to view more data
10
Literatures (Medical) associated with Xentuzumab01 Dec 2025BREAST
Artificial intelligence and radiomics biomarkers for treatment response prediction in advanced HER2-negative breast cancer
Article
Author: Schwartz, Lawrence H ; Schmitt, Julia ; Zhao, Binsheng ; Dercle, Laurent ; Amend, Mario ; McGale, Jeremy ; Peltzer, Alexander
STUDY AIM:
Despite the development of novel therapies, breast cancer mortality remains high. Improved treatment response assessment tools are needed. We aimed to test the transferability of externally validated AI/radiomics biomarkers for predicting treatment response in advanced, hormone receptor-positive (HR+), HER2-breast cancer treated with xentuzumab, exemestane, and everolimus.
METHODS:
Patient data from a phase Ib/II trial (May 2014-October 2016) were analyzed retrospectively. Eight imaging biomarkers (liver and overall tumor volume, two radiomics features representing tumor heterogeneity at both baseline and week 8) were validated for predicting clinical benefit using AUC analysis. An ancillary AI analysis developed a signature for predicting best overall response using 40 variables (3 clinical and 37 imaging) in the same cohort.
RESULTS:
Of 106 patients with data available for analysis, 28 had no clinical benefit from treatment (Group A) vs. 78 with clinical benefit (Group B). Seven of eight imaging biomarkers demonstrated significant predictive value. Participants in Group B exhibited significantly lower baseline and follow-up measures of liver and overall tumor volume, alongside marked changes in tumor heterogeneity by week 8. In our ancillary AI/radiomics model, the dominant drivers of prediction were changes in both liver tumor and overall tumor volume during treatment and the number of osteoblastic lesions on baseline bone scans.
CONCLUSION:
This cross-cancer proof-of-concept testing study supports the feasibility of applying multimodal AI/radiomics biomarkers to predict treatment response in advanced HR+, HER2- breast cancer, laying the foundation for broader pancancer and pantreatment applications pending further validation.
CLINICAL TRIAL REGISTRATION NUMBER:
NCT02123823.
01 Nov 2025ESMO Open
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer
Article
Author: Yee, D. ; Oliveira, M. ; Puig, M. ; Gonçalves, A. ; Sablin, M.P. ; Vidal, M. ; Lorence, R.M. ; Fukuyama, Y. ; LoRusso, P. ; Forman, N. ; Hardebeck, M.C. ; Stradella, A. ; Iwata, H.
BACKGROUND:
This phase Ib trial assessed the insulin-like growth factor 1/2 neutralizing antibody, xentuzumab, plus abemaciclib ± endocrine therapy (ET) in patients with advanced/metastatic solid tumors, including hormone receptor (HR)-positive breast cancer.
PATIENTS AND METHODS:
In part 1, patients with advanced solid tumors received escalating doses of xentuzumab + abemaciclib (cohort A). In part 2, dose-finding cohorts B-D had advanced/metastatic HR-positive, human epidermal growth factor receptor 2-negative breast cancer and received xentuzumab + abemaciclib plus letrozole, anastrozole, or fulvestrant. Part 3 included expansion cohorts assessing xentuzumab + abemaciclib plus fulvestrant in patients with HR-positive, human epidermal growth factor receptor 2-negative breast cancer with visceral (cohort D1) or non-visceral disease (cohort D2) who had progressed following ET, or non-visceral disease who had progressed following ET and a cyclin-dependent kinase inhibitor (cohort F). Primary endpoints were maximum tolerated dose (cohorts A-D), 18-month progression-free survival (cohort D1/D2) and disease control (cohort F). Comprehensive biomarker analyses were undertaken.
RESULTS:
A total of 133 patients were treated. The maximum tolerated dose was xentuzumab 1000 mg once weekly plus abemaciclib 150 mg twice daily (cohorts A-D). The most common grade ≥3 adverse event was decreased neutrophil count. Cohorts B-D demonstrated response rates of ≥25%. The 18-month progression-free survival rate in cohorts D1/D2 was 41.4%/78.5%. The disease control rate in cohort F was 40.0%. Biomarker analysis indicated target engagement. Prognostic biomarkers included total serum insulin-like growth factor 1 concentrations, expression of CCND1, and MCL-1 mutations.
CONCLUSIONS:
Xentuzumab + abemaciclib + ETs demonstrated manageable tolerability and promising efficacy, especially in patients with breast cancer and non-visceral metastases.
03 Apr 2023Molecular cancer therapeutics
Identification of
IGF2
as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Article
Author: Cairo, Stefano ; Armengol, Carolina ; Pinyol, Roser ; Morland, Bruce ; Sia, Daniela ; Torres-Martin, Miguel ; Childs, Margaret ; Andreu-Oller, Carmen ; Puigvehi, Marc ; Maibach, Rudolf ; Domingo-Sàbat, Montserrat ; Losic, Bojan ; Royo, Laura ; Haber, Philipp K. ; Guccione, Ernesto ; Czauderna, Piotr ; Akers, Nicholas K. ; Torrens, Laura ; Llovet, Josep M. ; Rialdi, Alex ; Montironi, Carla ; Peix, Judit ; Balaseviciute, Ugne ; Willoughby, Catherine E. ; Alaggio, Rita ; Carrillo-Reixach, Juan ; Del Río-Álvarez, Álvaro ; Mazzaferro, Vincenzo ; Abril-Fornaguera, Jordi
Abstract:
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of molecular therapies in preclinical models of HB. Paired tumor and adjacent tissues from 31 HBs and a validation set of 50 HBs were analyzed using RNA-seq, SNP, and methylation arrays. IGF2 overexpression was identified as the top targetable HB driver, present in 71% of HBs (22/31). IGF2high tumors displayed progenitor cell features and shorter recurrence-free survival. IGF2 overexpression was associated in 91% of cases with fetal promoter hypomethylation, ICR1 deregulation, 11p15.5 loss of heterozygosity or miR483-5p overexpression. The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. The combination of xentuzumab with cisplatin showed strong synergistic antitumor effects in organoids and in IGF2high cell lines. In mice (n = 55), the combination induced a significant decrease in tumor volume and improved survival compared with cisplatin alone. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.
100 Deals associated with Xentuzumab
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | Phase 2 | Italy | 14 Nov 2018 | |
| Metastatic breast cancer | Phase 2 | Italy | 14 Nov 2018 | |
| Adenocarcinoma of prostate | Phase 1 | United Kingdom | 17 Dec 2021 | |
| Prostate Cancer, Hereditary, 7 | Phase 1 | United Kingdom | 17 Dec 2021 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | United States | 04 May 2017 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | Japan | 04 May 2017 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | Denmark | 04 May 2017 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | Finland | 04 May 2017 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | France | 04 May 2017 | |
| Hormone receptor positive HER2 positive breast cancer | Phase 1 | South Korea | 04 May 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 164 | (Xentuzumab (BI 836845) 1000 mg + Everolimus 10 mg + Exemestane 25 mg - Phase II) | xdhqsjdytc(rtrkiolxnz) = kofzyppsob hvburyonxz (fywjoeykbo, ygtlzhvtff - oivohwncml) View more | - | 15 Jul 2025 | ||
(Everolimus 10 mg + Exemestane 25 mg - Phase II) | xdhqsjdytc(rtrkiolxnz) = ufnnrweoze hvburyonxz (fywjoeykbo, boxauivbkk - hdoclfoila) View more | ||||||
Phase 1 | 120 | (Phase Ib Escalation: 750 mg Xentuzumab + 160 mg Enzalutamide) | stcettsndq = kivvptoyoe behsoljclf (cfermtziug, hgirbmzrih - mcmezfyhaq) View more | - | 15 Jul 2025 | ||
(Phase Ib Escalation: 1000 mg Xentuzumab + 160 mg Enzalutamide) | stcettsndq = odpwfwwiwo behsoljclf (cfermtziug, wrdtplnilq - pvrbnietqe) View more | ||||||
Phase 1 | 32 | (Xentuzumab + Afatinib 30 Milligram (mg) - Part A) | cwnkxtcglz = jkcmstzxli dlpiqfbwuh (xypljumymf, ffwesefrho - snssuctagp) | - | 25 Jun 2025 | ||
(Xentuzumab + Afatinib 40 mg - Part A) | cwnkxtcglz = nawgbjjrhm dlpiqfbwuh (xypljumymf, ewxslqrybf - dqrkknqxcz) | ||||||
Phase 1 | 133 | (Cohort A: Xentuzumab 1000 mg & 150 mg Abemaciclib) | rgotchjfaj = paztiadmgs meyviyrzot (qxokbkmjdg, emfkpqarrv - mahfxkhvce) View more | - | 24 Jun 2025 | ||
(Cohort B: Xentuzumab 1000 mg & 150 mg Abemaciclib & 2.5 mg Letrozole) | rgotchjfaj = obihbmkcup meyviyrzot (qxokbkmjdg, bxspxflaym - fehqcaouyf) View more | ||||||
Phase 1 | 21 | (Xentuzumab (BI 836845)) | jkgcwwvxli = khmuwuvkbn dtylecziic (sxnrfjqram, ycuqvimpkr - odwattahuk) | - | 19 Jun 2025 | ||
(750 Milligram Xentuzumab (BI 836845)) | pmhmypivpv(izvokldwmn) = peoktptwgd sqtscptfdw (bahwrwtvjd, atxkmrsjat - fiakgzlbzv) View more | ||||||
Early Phase 1 | 27 | tgmmbpelbk(xgjwfefbvv) = lsdhhzpllw dvklyqfigb (faxxfterga, ycpsdewynb - ydtqtapldt) View more | - | 17 Feb 2025 | |||
Phase 2 | 103 | gunfawwias(uqkokzgctt) = zmxmexbmin khcfrmbtdq (lzcuvuktmb, 6.8 - 29.3) View more | Negative | 12 Jun 2023 | |||
Placebo | gunfawwias(uqkokzgctt) = bltuhzecdx khcfrmbtdq (lzcuvuktmb, 7.7 - 19.5) View more | ||||||
Phase 2 | 103 | (1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane) | vwqxxkkxcv(uwuymygbsa) = dshujkhlqr owoqilsbrf (lmkzwdmxfx, cnwstqzjah - iyqvwdhpru) View more | - | 29 Sep 2022 | ||
(Placebo + 10 mg Everolimus + 25 mg Exemestane) | vwqxxkkxcv(uwuymygbsa) = jprikixrop owoqilsbrf (lmkzwdmxfx, ubvxfrfpnt - zovukkcrve) View more | ||||||
Phase 1 | 21 | pbjeyalteg(gtuqxfvknb) = There were no dose-limiting toxicities at any dose. pnmuqbzrav (ocxwysrovt ) View more | Positive | 06 Dec 2021 | |||
NCT02191891 (Pubmed) Manual  | Phase 1 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR Positive | EGFR T790M Negative | 32 | (part A) | clvfrktxyg(guhiosvyne) = Maximum tolerated dose was xentuzumab 1000 mg/wk plus afatinib 40 mg/d. aisklvikzy (giujybqqaz ) View more | Negative | 10 Jul 2021 |
(part B) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free